Simeprevir functions as a direct-acting antiviral agent because it inhibits hepatitis C viral replication by binding to and inhibiting the protease, hepatitis C virus (HCV) NS3/4A.
Simeprevir is a protease inhibitor for HCV NS3/4A protease, which is required for replication of the virus.
Simeprevir is mainly metabolized by CYP3A enzymes.
In patients receiving the combination therapy, the most common adverse reactions were nausea, pruritus, photosensitivity, and rash.
On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.